19 results about "Inducible gene" patented technology

The application belongs to the technical field of molecular plant pathology, and particularly relates to a peanut disease-resistant gene AhNHL24 and application thereof. Through whole genome identification and bioinformatics analysis, 45 NHL family genes (AhNHL) are identified in peanuts, and gene expression analysis shows that most of the AhNHL genes can respond to the induction of biological stress and abiotic stress. Gene disease resistance identification finds that transient overexpression of AhNHL14, AhNHL24 and AhNHL31 can significantly improve the resistance of tobacco and peanuts to Pseudomonas solanacearum, and the disease resistance of AhNHL24 is the strongest. Through transgenic tobacco heterologous overexpression of AhNHL24 and inoculation experiments, it is shown that the peanut and tobacco plants overexpressing AhNHL24 not only have significantly enhanced resistance to Pseudomonas solanacearum, but also have significantly enhanced resistance to Sclerotium rofsii. The application provides an important basis for the cultivation of plant (peanut and tobacco, etc.) broad-spectrum disease-resistant varieties.

Provided is an agent for shortening the growth period of a plant, said agent comprising an active ingredient that is a compound represented by formula (I), a tautomer thereof, or an agriculturally acceptable salt of the compound or the tautomer.　(In formula (I), R1 and R2 each independently represent a hydrogen atom or a C1-4 alkyl group, and R3, R4, and R5 each independently represent a C1-4 alkyl group.)

A myogenin-expressing fibroblast-like cell (MEFLC) line and a construction method and a use thereof are provided. The MEFLC line was deposited in the Guangdong Microbial Culture Collection Center (GDMCC) on Apr. 23, 2022 with an accession number of GDMCC NO: 62409. The construction method includes: 1) constructing a pCW-MYOG-T2A-Puro lentivirus; 2) infecting a human induced pluripotent stem cell (iPSC) line with the lentivirus, inducing the expression of an MYOG gene, and screening out a positive monoclonal cell line; 3) subjecting the positive monoclonal cell line to expanded cultivation, during which the expression of the MYOG gene is continuously induced; and 4) changing cultivation conditions, continuously inducing the expression of the MYOG gene, and screening out positive monoclonal cell lines to ensure the purity of MYOG-positive cells until a cell morphology changes significantly into fibroblastoid cells to obtain the MEFLC line.

The application provides a LiCOMT gene for regulating synthesis of lycoris kingianus glycosides and application thereof, belongs to the technical field of plant genetic engineering, and the nucleotide sequence of the LiCOMT gene is shown as SEQ ID NO. 7, and the amino acid sequence of the encoded protein is shown as SEQ ID NO. 8; the application screens out a candidate gene LiCOMT significantly related to lycoris kingianus glycoside accumulation from lily bulb development period transcriptome data through weighted gene co-expression network analysis (WGCNA), and confirms that silencing the LiCOMT gene can reduce the content of lycoris kingianus glycoside A, lycoris kingianus glycoside B and lycoris kingianus glycoside F in lily bulbs by about 60%, 42% and 43% respectively by using a virus-induced gene silencing (VIGS) technique; and the application provides important gene resources and theoretical basis for lily secondary metabolism regulation and molecular breeding.

The application discloses a dsRNA molecule targeting VdIRE1 a gene and application thereof in prevention and treatment of verticillium wilt, and belongs to the technical field of biotechnology. VdIRE1 The application specifically discloses a dsRNA molecule which can target a Verticillium dahliae gene (coding the amino acid sequence shown in SEQ ID NO: 3) and inhibit expression of the gene, and a nucleotide sequence of a sense strand of the dsRNA molecule is selected from SEQ ID NO: 4 or SEQ ID NO: 5. Based on the molecule, the application further provides a recombinant carrier containing a coding sequence of the molecule, a recombinant microorganism, a transgenic disease-resistant plant and an RNAi pesticide preparation. The schemes can be realized by means of host-induced gene silencing, microorganism-mediated gene silencing or preparation treatment, and can effectively reduce virulence of a pathogenic bacterium, thereby providing a new technical approach for green prevention and control of verticillium wilt.

This invention relates to the Bg.MEW_38304 gene regulating plant growth and flowering, its encoded protein, and its applications, belonging to the fields of plant molecular biotechnology and genetic engineering. This gene is derived from *Prunus glabra*, with a full-length CDS sequence of 378 bp. The encoded protein contains a conserved SBP domain, and its nucleotide sequence is shown in SEQ ID NO.1. It was cloned from the bracts of the 'Snow White' variety at the BR3 stage. Bioinformatics analysis, subcellular localization, virus-induced gene silencing, and heterologous overexpression experiments verified that the protein encoded by this gene is located in the cell nucleus and cell membrane. Silencing this gene leads to bract and stem / leaf abortion in *Prunus glabra*, while overexpression promotes growth and earlier flowering in *Arabidopsis thaliana*. This application identifies a key gene for *Prunus glabra* bract development, which can be used to promote plant growth and flowering, and has important application value in the molecular breeding of ornamental plants.

The process of inducing pre-mRNA splicing was disclosed. CD33 Novel antisense oligonucleotides that skip exon 2 in genes and their potential applications in treating neurodegenerative diseases such as Alzheimer's disease.

The application provides application of MdPHY7 protein or MdPHY7 gene related to apple anthocyanin biosynthesis in regulation of apple anthocyanin synthesis, and belongs to the technical field of plant genetic engineering. Exogenous ALA treatment can induce MdPHY7 gene expression, thereby promoting anthocyanin synthesis increase, finally causing apple anthocyanin accumulation and promoting fruit coloring. It has been verified that overexpression of MdPHY7 gene can promote apple anthocyanin accumulation, while interference with MdPHY7 gene expression can inhibit anthocyanin accumulation and further inhibit fruit appearance quality improvement. It can be seen that MdPHY7 is a new key gene for regulating apple anthocyanin accumulation, and plays a key role in ALA regulation of apple anthocyanin accumulation, which has far-reaching significance for agricultural and forestry production, and lays a solid theoretical foundation for application of ALA in the field of agricultural production.

A plant growth period shortening agent comprising an active ingredient which is a compound represented by the following formula (I), a tautomeric isomer thereof, or an agronomically acceptable salt thereof. (In formula (I), R1 and R2 independently represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R3, R4 and R5 independently represent an alkyl group having 1 to 4 carbon atoms.)… (I)

The application discloses an antisense oligonucleotide for inducing skipping of the 11th exon of a NOTCH3 gene, a pharmaceutical composition thereof and application thereof. The application provides six candidate sequences of ASO12, ASO15, ASO16, ASO17, ASO19 and ASO20 for efficiently inducing exon skipping, wherein the half effective concentration (EC50) of ASO17 is as low as 36.53 nM. The application also provides a pharmaceutical composition containing the antisense oligonucleotide and application thereof in preparation of a medicine for treating CADASIL, and is especially suitable for a Chinese CADASIL patient population carrying a mutation of the 11th exon of a NOTCH3 gene. It is verified through experiments that the truncated NOTCH3 protein produced by skipping the 11th exon retains normal expression level, subcellular localization and signal transduction function, and meanwhile, pathogenic protein aggregation is reduced. The application fills the blank of specific treatment of CADASIL for Chinese population, and has clear clinical conversion value.

The application relates to a genetically engineered body, and particularly discloses a perilla frutescens PfCHLH gene and a virus-induced gene silencing system, a construction method and application of the gene silencing system. PfCHLH The nucleotide sequence of the gene is shown as SEQ ID NO. 1, and the amino acid sequence of the encoded protein is shown as SEQ ID NO. 2. PfCHLH The gene silencing fragment is cloned into a virus carrier pTRV2 to obtain a pTRV2- PfCHLH silencing carrier, and the pTRV2 carrier and the pTRV1 carrier are respectively transformed into agrobacterium GV3101 to prepare infection bacterial liquid; the infection bacterial liquid is mixed according to a volume ratio of 1:1 and then injected into perilla frutescens cotyledons to induce gene silencing. PfCHLH qRT-PCR verification shows that the expression amount is significantly down-regulated and a stable yellowing phenotype is generated; preferably, the OD 600 of the infection bacterial liquid is 0.6, the silencing phenotype is more significant, and the consistency is better. The perilla frutescens VIGS system established in the application is simple in operation, short in cycle, and high in efficiency, and can be used for rapid identification of perilla frutescens gene functions and verification and application of key genes in related metabolic pathways.

The present invention belongs to the fields of biotechnology and plant breeding. Specifically disclosed are a gene having parthenogenesis-inducing ability in plants, and the use thereof in plant breeding such as induction of haploid formation and apomixis. By means of regulating the expression of a gene that encodes a protein having parthenogenesis-inducing ability, the transition of egg cells into the embryonic development fate is effectively realized, thereby inducing parthenogenesis. The gene and a corresponding induction method therefor can be applied to related plant breeding processes such as the production of haploids and synthetic apomixis.

This invention discloses a pathogenic gene, protein, and application of *Verticillium dahliae*. This invention relates to the field of biotechnology and provides a method for controlling *Verticillium dahliae* wilt based on RNAi (RNA interference), along with its related components and applications. Specifically, it discloses the method of inhibiting or silencing the pathogenic gene of *Verticillium dahliae*. VdHDAC The application of the expression method (whose encoded protein is shown in SEQ ID NO:3) for the prevention and control of Verticillium wilt relies on providing a class of dsRNA molecules that can target this gene, with the positive strand preferably selected from SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:11. Based on this molecule, this invention further provides recombinant vectors containing its coding sequence, recombinant microorganisms, transgenic disease-resistant plants, and RNAi pesticide formulations. These methods can be achieved through host-induced gene silencing, microorganism-mediated gene silencing, or formulation treatment, effectively reducing the virulence of the pathogen and providing a new technical approach for the green control of Verticillium wilt.

The application discloses application of FGSG_09291 protein and a coding gene thereof in improving plant disease resistance, and belongs to the technical field of plant immune induction. A new FGSG_09291 protein with plant immune activation function is found from Fusarium graminearum, and the FGSG_09291 protein can promote active oxygen burst and callose accumulation of plants, and provide basic immune response for the plants. PR1a genes, WRKY70 genes and LOX3 high expression of the genes, PR1a and WRKY70 the genes are genes of a salicylic acid pathway, and increase of the salicylic acid can improve broad-spectrum resistance of the plants. It is verified through experiments that the FGSG_09291 protein can enhance the prevention and control effect of corn on the stunt disease.

The invention relates to the technical field of biomedical materials, discloses a preparation method of a bone repair mineralized biological membrane capable of inducing gene expression and a product, and aims at solving the problems that an existing bone repair material HAP crystal is difficult to regulate and control, the mechanical activity and the biological activity are not matched, bone induction is weak, the process is complex and the like. The preparation method comprises the following steps: S1, preparing a decellularized small intestinal submucosa (SIS) membrane and sterilizing; s2, constructing a pDA-PAM (at) SIS composite membrane; s3, inducing directional growth of HAP through ion permeation biomimetic mineralization; and S4, cleaning and drying to obtain the HAP / SIS collagen mineralized biological membrane. The product contains an SIS collagen matrix and low-crystallinity nano HAP (the width is 4-20nm, the length is 31-105nm, and the product is oriented along a c axis), the tensile strength is greater than or equal to 13MPa, the elastic modulus is greater than or equal to 75MPa, the specific surface area is greater than or equal to 60m < 2 > / g, and osteogenic genes such as ALP, Runx2 and the like can be up-regulated by more than or equal to 2 times. The method is mild in process, easy to operate, good in biocompatibility, high in bone conduction and inductivity, suitable for large-scale production and capable of meeting the clinical bone defect repair requirement.

The application discloses application of a RIG-I inhibitor in myocardial ischemia-reperfusion injury. By conditionally knocking out a RIG-I gene in myocardial cells, it is found that RIG-I protein in myocardial cells participates in and relieves myocardial ischemia-reperfusion injury of mice, and it is determined that retinoic acid-inducible gene I (RIG-I, also known as DDX58) is a key treatment target. Further, by computer-aided drug design, a RIG-I specific small molecule inhibitor RI-Q1 is screened and obtained, and it is proved that the small molecule inhibitor can effectively inhibit pyroptosis inflammation of myocardial cells, thereby preventing or treating MI / RI. The small molecule inhibitor RI-Q1 is easy to obtain, can directly inhibit RIG-I protein activity, and significantly reduces pyroptosis and inflammatory reaction of myocardial cells. Therefore, as a novel small molecule compound targeting RIG-I, the small molecule inhibitor RI-Q1 provides a new drug development direction and application prospect for treatment of MI / RI.